Table 4.
Selected miRNAs showing differential concentration changes between IMA and PMA patients
| Starting fraction | miRNA | I(MA)-AVE (log2CPM) | P(MA)-AVE (log2CPM) | Log2FC | P |
|---|---|---|---|---|---|
| Urine | hsa-miR-10a-5p | 10.16 | 13.52 | 3.36 | 0.0048 |
| hsa-miR-10b-5p | 10.33 | 12.97 | 2.65 | 0.0408 | |
| hsa-miR-124-1-3p | 11.16 | 8.97 | -2.19 | 0.0448 | |
| hsa-miR-141-3p | 7.61 | 10.88 | 3.27 | 0.0129 | |
| hsa-miR-148a-3p | 11.72 | 12.79 | 1.07 | 0.0428 | |
| hsa-miR-183-5p | 7.10 | 9.58 | 2.48 | 0.0428 | |
| hsa-miR-192-5p | 9.13 | 11.92 | 2.79 | 0.0222 | |
| hsa-miR-200a-3p | 9.16 | 12.44 | 3.29 | 0.0069 | |
| hsa-miR-200c-3p | 10.19 | 13.04 | 2.85 | 0.0202 | |
| hsa-miR-29b-1-3p ♂ | 9.29 | 10.57 | 1.28 | 0.0017 | |
| hsa-miR-30b-5p | 10.80 | 12.27 | 1.46 | 0.0169 | |
| hsa-miR-31-5p | 7.47 | 9.81 | 2.33 | 0.0005 | |
| EV | hsa-miR-200c-3p | 11.78 | 13.58 | 1.80 | 0.0351 |
| hsa-miR-31-5p | 9.34 | 10.92 | 1.58 | 0.0343 | |
| hsa-miR-373-3p | 10.35 | 11.92 | 1.57 | 0.0495 | |
| hsa-miR-451a-5p | 17.32 | 15.95 | -1.38 | 0.0166 | |
| hsa-miR-362-5p | 8.63 | 9.98 | 1.34 | 0.0195 | |
| hsa-miR-28-3p | 8.20 | 9.48 | 1.28 | 0.0116 | |
| hsa-miR-660-5p | 9.95 | 11.14 | 1.19 | 0.0173 | |
| hsa-miR-99b-5p | 10.38 | 11.52 | 1.14 | 0.0250 | |
| hsa-miR-122-5p | 10.60 | 9.48 | -1.12 | 0.0284 | |
| hsa-miR-21-5p | 15.29 | 16.29 | 0.99 | 0.0291 | |
| hsa-miR-30d-5p | 13.63 | 14.59 | 0.96 | 0.0468 | |
| hsa-miR-101-1-3p | 13.57 | 12.82 | -0.75 | 0.0008 |
AVE, average; CPM, counts per million; EV, extracellular vesicle; FC, fold change; I(MA) = intermittent MA: MA cycle; MA, microalbuminuria; miRNA, microRNA; P(MA), persistent MA:MA cycle.
♂ (male) or ♀ (female) designates gender-specific enrichment for a given miRNAs. See Supplementary Table S3 for additional details.